There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Castle Biosciences (CSTL – Research Report), Karuna Therapeutics (KRTX – Research Report) and Gracell Biotechnologies (GRCL – Research Report) with bullish sentiments.
Castle Biosciences (CSTL)
In a report released yesterday, Mark Massaro from BTIG reiterated a Buy rating on Castle Biosciences, with a price target of $38.00. The company’s shares closed last Thursday at $21.05.
According to TipRanks.com, Massaro has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -7.7% and a 38.1% success rate. Massaro covers the Healthcare sector, focusing on stocks such as MDxHealth S.A. Sponsored ADR, Ginkgo Bioworks Holdings, and Adaptive Biotechnologies.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Castle Biosciences with a $40.20 average price target.
See the top stocks recommended by analysts >>
Karuna Therapeutics (KRTX)
H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Karuna Therapeutics today and set a price target of $300.00. The company’s shares closed last Thursday at $229.26.
According to TipRanks.com, Selvaraju is ranked 0 out of 5 stars with an average return of -16.9% and a 29.2% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Reviva Pharmaceuticals Holdings, MoonLake Immunotherapeutics, and Entrada Therapeutics Inc.
Currently, the analyst consensus on Karuna Therapeutics is a Strong Buy with an average price target of $272.86, which is a 19.9% upside from current levels. In a report issued on May 21, Mizuho Securities also reiterated a Buy rating on the stock with a $274.00 price target.
Gracell Biotechnologies (GRCL)
BTIG analyst Justin Zelin maintained a Buy rating on Gracell Biotechnologies yesterday and set a price target of $18.00. The company’s shares closed last Thursday at $2.98.
According to TipRanks.com, Zelin is a 4-star analyst with an average return of 8.9% and a 40.5% success rate. Zelin covers the Healthcare sector, focusing on stocks such as Syndax Pharmaceuticals, Precision BioSciences, and Poseida Therapeutics.
Currently, the analyst consensus on Gracell Biotechnologies is a Strong Buy with an average price target of $12.25, implying a 334.4% upside from current levels. In a report issued on May 22, H.C. Wainwright also maintained a Buy rating on the stock with a $12.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on CSTL: